رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06077201 (HOMERUNHITTER) لـ مرض القلب الصمامي هي قيد التجنيد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions (HOMERUNHITTER)
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ 'رادار التجارب AI' أن يساعدك؛ ما عليك سوى النقر على 'وصف الدراسة' لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06077201 (HOMERUNHITTER) هي دراسة تدخُّلية لـمرض القلب الصمامي وهي قيد التجنيد. بدأت في ٢ جمادى الآخرة ١٤٤٥ هـ مع خطة لتجنيد ٣٧٥ مشاركًا. يقودها جامعة فاندربيلت، ومن المتوقع اكتمالها بحلول ٢٠ ربيع الآخر ١٤٤٨ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٣ ربيع الأول ١٤٤٧ هـ.
الملخص
The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off/interactive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry.
العنوان الرسمي
Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions
الحالات الطبية
مرض القلب الصماميمعرّفات دراسة أخرى
- HOMERUNHITTER
- 222231
- 5R01AG073633-02 (منحة/عقد NIH الأمريكي)
NCT معرّف
تاريخ البدء (فعلي)
2023-12-15
آخر تحديث مُنشور
2025-08-26
تاريخ الاكتمال (المقدر)
2026-10-01
عدد المشاركين المخطط لهم
٣٧٥
نوع الدراسة
تدخُّلية
المرحلة
غ/م
الحالة
قيد التجنيد
الكلمات الرئيسية
cardiac rehabilitation
transcatheter heart valve intervention
cardiology
aortic stenosis
mitral regurgitation
tricuspid regurgitation
transcatheter heart valve intervention
cardiology
aortic stenosis
mitral regurgitation
tricuspid regurgitation
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
أحادي
مجموعات/التدخلات
| مجموعة المشاركين/مجموعة | تَدَخُّل/علاج |
|---|---|
بدون تدخلControl Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living. | غ/م |
تجريبيةHBCR hands-off Home-based cardiac rehabilitation with mobile application + AHA Life's Essential 8 sheets. | HBCR Hands-off Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. |
تجريبيةHBCR interactive Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets. | HBCR Interactive Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist. |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Probability of the hierarchical clinical event composite | The hierarchical clinical event composite includes (in order of hierarchy): (1) all-cause death; (2) all-cause hospitalization; and (3) skilled nursing facility visits. To examine whether the intervention improves mortality, hospitalization, and SNF rates after THVIs, we will conduct Bayesian Markov longitudinal proportional odds model on weekly outcome measures. The pooled active treatment vs. control group comparison (primary comparison for the trial) will be estimated by contrasting the average of posterior probability that Y≥y of the two active treatment groups (hands-off HBCR and interactive HBCR) to the control group. | Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months). |
Average daily total activity counts | Daily total activity counts are determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The primary comparison will be at 12 weeks after randomization. |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Average daily total activity counts | Daily total activity counts are determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The secondary comparisons will be at 24 and 52 weeks after randomization. |
Average daily active minutes | Daily active minutes are determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily active minutes determined. The comparisons will be at 12, 24 and 52 weeks after randomization. |
Average daily steps | Daily steps are determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparisons will be at 12, 24 and 52 weeks after randomization. |
Average daily energy expenditure | Daily energy expenditure is determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily energy expenditure determined. The comparisons will be at 12, 24 and 52 weeks after randomization. |
Average daily moderate to vigorous active minutes | Daily moderate to vigorous active minutes are determined by a triaxial actigraphy device. | The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily moderate to vigorous active mins determined. The comparisons will be at 12, 24 and 52 weeks after randomization. |
6 minute walk distance | The distance walked in 6 minutes. | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Chair sit to stand time | The time taken to complete 5 chair rises. | The comparisons will be at 12, 24 and 52 weeks after randomization. |
5 meter gait speed | The speed of walking 5 meters (meters/second). | The comparisons will be at 12, 24 and 52 weeks after randomization. |
All-cause hospitalizations | Hospitalizations for any reason | Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months). |
All-cause death | Death for any cause | Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months). |
Heart-failure specific health status assessed by the KCCQ | Assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ); (score range 0-100, higher is better health status) | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Physical health status assessed by the PROMIS 10 | Global physical health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20 with corresponding T score and SE, higher is better) | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Mental health status assessed by the PROMIS 10 | Global mental health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20 with corresponding T score and SE, higher is better) | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Mood disturbance assessed by PHQ9 | Patient health questionnaire 9 (PHQ9); (score range 1-27, higher score worse) | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Patient goals progress score | A patient goals progress score (-3 to +3) will be determined for 5 domains and the scores combined for a global score from -15 to +15. | The comparisons will be at 12, 24 and 52 weeks after randomization. |
Basic mobility by AM-PAC | Basic mobility will be assessed with the Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Outpatient Short Form (Low Function); (raw score range 0-39 with corresponding T-score and SE, higher score is better) | The comparisons will be at 12, 24 and 52 weeks after randomization. |
معايير الأهلية
الأعمار المؤهلة للدراسة
بالغ, كبار السن
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
الكل
- Treated with a transcatheter heart valve intervention (e.g., transcatheter aortic valve implantation [in the native valve or valve-in-valve], mitral transcatheter edge-to-edge repair, mitral valve-in-valve) of the aortic, mitral, or tricuspid valve done via transfemoral access
- Unwilling or unable to provide informed consent
- Not adherent to wearing the ActiGraph activity tracker during the roll-in phase for a minimum of 4 (out of 7) compliant days (worn >10 hours/day)
- Planned participation in center based cardiac rehabilitation (CBCR)
- Transcatheter heart valve intervention done via any route other than a transfemoral approach
- Stroke during or immediately after the transcatheter heart valve intervention prior to randomization
- Placement of a pacemaker within 6 weeks prior to the transcatheter heart valve intervention or after the transcatheter heart valve intervention and prior to randomization
- Those who require a walker or who cannot get out of a chair/bed on their own and walk independently (use of a cane is acceptable)
- Physical or neuropsychiatric limitations that would prevent proficient use of the study tools and successful completion of the physical and quality of life assessments (e.g. blindness, dementia)
- Planned surgery within 6 months after the heart valve intervention
- Planned discharge from hospital to hospice, assisted living, or inpatient rehabilitation facility (discharge to a senior facility permitted as long as they are considered Independent Living)
- Treating provider or site PI indicates that participation in the study would be unsafe
- Participation in any ongoing randomized trial that has not completed follow-up unless the sponsor of the other trial allows enrollment of the participant in this cardiac rehabilitation trial
- Unable to complete the baseline study visit prior to 6 weeks after the transcatheter heart valve intervention
جامعة كارولاينا الجنوبية الطبية كلية الطب253 تجارب سريرية نشطة للاستكشاف
جامعة بيتسبرغ543 تجارب سريرية نشطة للاستكشاف
- 🔬Duke Clinical Research Institute
- 🏛️National Institute on Aging (NIA)
جامعة ميشيغان488 تجارب سريرية نشطة للاستكشاف
- 🏥The Cleveland Clinic
كولورادو دينفر489 تجارب سريرية نشطة للاستكشاف
- ⚕️Piedmont Healthcare
جامعة ويك فورست323 تجارب سريرية نشطة للاستكشاف
- ⚕️Morristown Medical Center
الجهة المسؤولة عن الدراسة
Brian Lindman, المحقق الرئيسي, Medical Director, Associate Professor of Medicine, Vanderbilt University Medical Center
جهة اتصال مركزية للدراسة
جهة اتصال: Anna Vatterott, MPH, 615-936-5798, [email protected]
جهة اتصال: Caleb Hayes, MPH, [email protected]
1 مواقع الدراسة في 1 بلدان
Tennessee
Vanderbilt University Medical Center, Nashville, Tennessee, 37203, United States
Anna Vatterott, MPH, جهة اتصال, 615-936-5798, [email protected]
Caleb Hayes, MPH, جهة اتصال, [email protected]
Brian R. Lindman, MD, MSc, المحقق الرئيسي
قيد التجنيد